Signals, Powered By EquityPandit
Lupin has received final approval from the US health regulator, for its Oseltamivir Phosphate.
In a BSE filing the company stated that, it has received final approval to market its generic Oseltamivir Phosphate, for oral suspension used for treating acute influenza, from the United States Food and Drug Administration (USFDA).
Moreover, this is a generic version of Hoffman-La Roche Inc’s Tamiflu for oral suspension, 6 mg/mL. Further the company stated, the product is “indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours and prophylaxis of influenza A and B in patients 1 year and older.”
